Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Neuroendocrine 1

Interventions

Specimen Handling 336 Magnetic Resonance Spectroscopy 332 Radiotherapy 314 Cyclophosphamide 296 pembrolizumab 283 Cisplatin 266 Carboplatin 246 Drug Therapy 237 Blood Specimen Collection 233 Biopsy 205 Bevacizumab 188 Gemcitabine 176 venetoclax 171 Radiosurgery 169 Capecitabine 165 Oxaliplatin 163 fludarabine 160 Paclitaxel 156 Nivolumab 156 Standard of Care 138 Surveys and Questionnaires 131 Surgical Procedures, Operative 131 Dexamethasone 126 Fluorouracil 125 Docetaxel 113 tislelizumab 110 Rituximab 110 Cytarabine 104 atezolizumab 101 Azacitidine 101

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × OTHER × DLL3 protein, human × Clear all

NCT06893783 2026-04-13

DeLLight

Asan Medical Center

Phase 2 Recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡